公开(公告)号：US10378058B2

公开(公告)日：2019-08-13

申请号：US12943644

申请日：2010-11-10

申请人： Dihua Yu ,  Xiaoyan Zhou ,  Yoichi Nagata ,  Francisco J. Esteva ,  Aysegul A. Sahin

发明人： Dihua Yu ,  Xiaoyan Zhou ,  Yoichi Nagata ,  Francisco J. Esteva ,  Aysegul A. Sahin

IPC分类号： C12Q1/6886 ,  C12Q1/42 ,  G01N33/50 ,  G01N33/573 ,  G01N33/574

摘要： Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.

公开(公告)号：US07981618B2

公开(公告)日：2011-07-19

申请号：US10983011

申请日：2004-11-05

申请人： Dihua Yu ,  Xiaoyan Zhou ,  Yoichi Nagata ,  Francisco J. Esteva ,  Aysegul A. Sahin

发明人： Dihua Yu ,  Xiaoyan Zhou ,  Yoichi Nagata ,  Francisco J. Esteva ,  Aysegul A. Sahin

IPC分类号： C12Q1/00 ,  G01N1/00 ,  G01N33/48 ,  G01N33/53 ,  G01N33/567 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  C12Q1/42 ,  C12Q2600/106 ,  G01N33/5011 ,  G01N33/573 ,  G01N33/57415 ,  Y10T436/25

摘要： Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.

摘要翻译： 患有ErbB2过度表达癌症的患者可以给予ErbB2靶向药物作为治疗方案，但并不是所有患者都有反应。 本发明涉及用于通过评估PTEN表达来评价ErbB2靶向剂在ErbB2过表达癌症中的潜在功效的诊断，预后和治疗方法和组合物，其是预测对ErbB2靶向剂（例如曲妥珠单抗）的反应性或抗性。 低PTEN表达预测了对曲妥单抗敏感的患者。

公开(公告)号：US20120039875A1

公开(公告)日：2012-02-16

申请号：US13184269

申请日：2011-07-15

申请人： Dihua Yu ,  Xiaoyan Zhou ,  Yoichi Nagata ,  Francisco J. Esteva ,  Aysegul A. Sahin

发明人： Dihua Yu ,  Xiaoyan Zhou ,  Yoichi Nagata ,  Francisco J. Esteva ,  Aysegul A. Sahin

IPC分类号： A61K39/395 ,  A61P35/00 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q1/42 ,  C12Q2600/106 ,  G01N33/5011 ,  G01N33/573 ,  G01N33/57415 ,  Y10T436/25

摘要： Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.

摘要翻译： 患有ErbB2过度表达癌症的患者可以给予ErbB2靶向药物作为治疗方案，但并不是所有患者都有反应。 本发明涉及用于通过评估PTEN表达来评价ErbB2靶向剂在ErbB2过表达癌症中的潜在功效的诊断，预后和治疗方法和组合物，其是预测对ErbB2靶向剂（例如曲妥珠单抗）的反应性或抗性。 低PTEN表达预测了对曲妥单抗敏感的患者。

公开(公告)号：US20110150868A1

公开(公告)日：2011-06-23

申请号：US12943644

申请日：2010-11-10

申请人： Dihua Yu ,  Xiaoyan Zhou ,  Yoichi Nagata ,  Francisco J. Esteva ,  Aysegul A. Sahin

发明人： Dihua Yu ,  Xiaoyan Zhou ,  Yoichi Nagata ,  Francisco J. Esteva ,  Aysegul A. Sahin

IPC分类号： A61K39/395 ,  A61P35/00 ,  C12Q1/68 ,  G01N33/573 ,  C12Q1/42

CPC分类号： C12Q1/6886 ,  C12Q1/42 ,  C12Q2600/106 ,  G01N33/5011 ,  G01N33/573 ,  G01N33/57415 ,  Y10T436/25

摘要： Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.

摘要翻译： 患有ErbB2过度表达癌症的患者可以给予ErbB2靶向药物作为治疗方案，但并不是所有患者都有反应。 本发明涉及用于通过评估PTEN表达来评价ErbB2靶向剂在ErbB2过表达癌症中的潜在功效的诊断，预后和治疗方法和组合物，其是预测对ErbB2靶向剂（例如曲妥珠单抗）的反应性或抗性。 低PTEN表达预测了对曲妥单抗敏感的患者。

公开(公告)号：US20130005592A1

公开(公告)日：2013-01-03

申请号：US13394936

申请日：2010-09-10

申请人： Steven Stone ,  Alexander Gutin ,  Darl Flake ,  Francisco J. Esteva ,  Dihua Yu

发明人： Steven Stone ,  Alexander Gutin ,  Darl Flake ,  Francisco J. Esteva ,  Dihua Yu

IPC分类号： C40B30/04 ,  C12Q1/68 ,  G01N33/574 ,  C07H21/04

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158

摘要： The invention generally relates to molecular diagnostics, and particularly to molecular markers for cancer therapy response and methods of use thereof.

摘要翻译： 本发明一般涉及分子诊断，特别涉及癌症治疗反应的分子标记及其使用方法。